Navigation Links
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
Date:7/23/2013

RRY-502 is an oral, potent and highly selective CRTh2 antagonist designed to treat patients with allergic asthma.  The CRTh2 receptor is expressed on Th2 T cells, basophils and eosinophils, and its ligand, prostaglandin D2 (PGD2), is released by mast cells.  The results of this study demonstrate that the PGD2/CRTh2 axis plays a key role in the migration and activation of inflammatory cells leading to many symptoms of asthma including coughing, difficulty breathing and exacerbations.  Because current asthma therapies do not fully target the Th2 pathway, antagonism of CRTh2 represents an exciting new approach to enhance disease control. 

Based on its mechanism of action, ARRY-502 may provide the most patient benefit in a Th2 gene signature-enriched population.  Several baseline Th2-related biomarkers were evaluated in the Phase 2 study.  The Th2 gene signature, which is present in about half of the asthma population, spans mild, moderate and severe disease and suggests broad applicability for ARRY-502 in these patients as well as in other Th2-driven diseases like allergic rhinitis and atopic dermatitis. 

About AsthmaIt is estimated that approximately 25 million people in the United States have asthma causing significant morbidity and mortality.  The worldwide estimates are between 235-300 million people with 180,000 deaths annually.  Despite the range of available asthma treatments, there remains a significant need for a convenient, safe and effective therapy for patients.  Specifically, oral medications may provide improved adherence relative to inhaled and injectable therapies. 

About Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Enterprise Europe Network - Sport Meets Business: How Entrepreneurs Beat the Recession
3. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
4. Omnetics Meets Increasing Demands of Miniature Electronics Industry with Custom Designed Micro and Nano Cables
5. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
6. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
7. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
10. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
11. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014  Decision Resources Group ... (P&R) decision criteria and payer requirements in ... into each country, allow pharma to leverage ... Global market access is extremely complex, with ... requirements and challenges—and a vast variety of ...
(Date:9/23/2014)... 23, 2014 Research and Markets  has announced ... report to their offering. Diabetes is ... globe. Over 382 million people are estimated to be currently ... to 592 million by 2035. With a very high ... and India , an increasing ...
(Date:9/23/2014)... DUBLIN , September 23, 2014 /PRNewswire/ ... ) has announced the addition of the  ...  report to their offering.  ... injectable drug delivery market holds significant potential ... with vials and painful needles to the ...
Breaking Medicine Technology:Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 2Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 3Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 4Glycated Haemoglobin (HbA1c) Testing Market 2Glycated Haemoglobin (HbA1c) Testing Market 3Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5
... February 23 BN,ImmunoTherapeutics, Inc. today provided updated ... vaccine, MVA-BN(R)-HER2, in development as,therapy of metastatic breast ... its primary endpoint with regards to safety and ... immune response was,detected in approximately 70% of evaluated ...
... An international team of,researchers has evaluated ... the knee, and the results have been ... journal "Osteoarthritis and Cartilage".,The researchers followed 376 ... treatments. After six months as well as ...
Cached Medicine Technology:BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 2BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 3New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years 2
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... cholesterol-lowering drugs while in the hospital for a hemorrhagic stroke ... than four times more likely to survive than people who ... People taking the commonly used drugs known as statins were ... to a rehabilitation facility, the study reports. When it ...
(Date:9/23/2014)... Investigators at Cincinnati Children,s Hospital Medical Center have ... gastritis (EG). The study, published in The ... that EG is a systemic disorder that has ... gastrointestinal tract, involves a series of allergy-associated-immune mechanisms ... is distinct from that of a related disorder, ...
(Date:9/23/2014)... Klose, professor of biology and a researcher in UTSA,s ... up with researchers at Ruhr University in Bochum, Germany ... findings were released this week in an article published ... Sciences . , Cholera is an acute infection caused ... with the bacterium Vibrio cholerae . An estimated ...
(Date:9/23/2014)... The community college system represents a potential source ... who will serve poor communities; however, there are ... colleges to four-year universities to medical schools. The ... recruitment, outreach and admissions practices be more inclusive ... Researchers from UCLA, UC San Francisco and San ...
(Date:9/23/2014)... "Obamacare" was signed into law in 2010 ... system since the 1960s. Designed to provide medical care ... an unwarranted intrusion into the affairs of private businesses ... healthcare systems in six Western countries, published last month ... move away from privatized medicine toward state-sponsored healthcare systems. ...
Breaking Medicine News(10 mins):Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2Health News:Medical students who attended community college likelier to serve poor communities 2Health News:Life, liberty, and the pursuit of healthcare? 2
... BIRMINGHAM, Ala. Leading high-performance computing engineers and ... University of Alabama at Birmingham (UAB) have called ... group says growing world-wide computer use puts more ... projects that are stored digitally at risk for ...
... lanes could protect more riders, researchers say , WEDNESDAY, Oct. ... and longer hospital stays, with both worsening over the past ... results of a study of biking injuries. , Chest injuries ... last five years, the study authors found. Cyclists themselves appear ...
... , MENLO PARK, Calif., Oct. 14 New Enterprise Associates, ... that Ravi Viswanathan, PhD, has been promoted to General Partner. ... on energy and growth equity information technology investments, as well ... Frank Torti, MD, to Principal. Dr. Torti joined NEA in ...
... ... industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) ... ... a global health care company in the emerging medical tourism industry, announced the addition of ...
... As the leaves begin to change color and ... today announced the launch of "A BETTER BEDTIME," its 2009-2010 ... campaign is based online at the Official Pajama Program A ... , Pajama Program provides new pajamas and new books to ...
... a third of deaths, study finds, , WEDNESDAY, Oct. 14 (HealthDay ... who share a bed or sofa with a parent, and alcohol ... many of the cases, says a U.K. study. , Researchers analyzed ... between January 2003 and December 2006. Of the deaths, 54 percent ...
Cached Medicine News:Health News:UAB international conference focuses on preventing high-capacity computer data theft 2Health News:As More Cyclists Hit the Road, Serious Injuries Rise 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 3Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 4Health News:Shared Bed May Raise SIDS Risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: